Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18308762 | 1.00 | RARB (0.35) | RARBESR2DGAT1SOAT1HSD17B1 | |
| SCHEMBL18308764 | 0.91 | RARB (0.35) | RARBESR2DGAT1SOAT1HSD17B1 | |
| SCHEMBL18308757 | 0.91 | RARB (0.35) | RARBESR2DGAT1SOAT1HSD17B1 | |
| SCHEMBL18308735 | 0.89 | RARB (0.36) | RARBESR2DGAT1SOAT1HSD17B1 | |
| SCHEMBL18308728 | 0.89 | RARB (0.36) | RARBESR2DGAT1SOAT1HSD17B1 | |
| SCHEMBL18308773 | 0.88 | ESR1 (0.31) | ESR2ESR1ALDH1A1CYP3A4TSHR | |
| SCHEMBL18806010 | 0.88 | ESR2 (0.33) | RARBESR2DGAT1SOAT1HSD17B1 | |
| SCHEMBL18308742 | 0.87 | ESR2 (0.41) | RARBESR2HSD17B1ESR1ALDH1A1 | |
| SCHEMBL18308780 | 0.86 | RXRA (0.31) | FYNRXRARXRBRXRG | |
| SCHEMBL18308784 | 0.86 | RXRA (0.31) | FYNRXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718791-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2023-08-08 | — | — | US | disclosed |
| US-20180201837-A1 | Method of Reducing ODF Mura in Polymer Stabilised Liquid Crystal Displays | MERCK PATENT GMBH (DE) | 2018-07-19 | — | — | US | disclosed |
| US-20170121606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | GMBH, MERCK PATENT (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20160362606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718791-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | VCL, ILK, LCP1 | RARB 3699/4885ESR2 4146/4885DGAT1 2814/4885 |
| US-20170121606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | VCL, LCP1, MAP1LC3C | RARB 3023/4885ESR2 4322/4885DGAT1 2980/4885 |
| US-20160362606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | VCL, PLEC, EML4 | RARB 2523/4885ESR2 4381/4885DGAT1 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.